325 related articles for article (PubMed ID: 15855574)
1. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
2. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
3. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
[TBL] [Abstract][Full Text] [Related]
4. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
5. A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.
Korsatko S; Glettler K; Olsen KJ; Wutte A; Bock G; Koehler G; Mader JK; Semlitsch B; Pieber TR
Diabetes Obes Metab; 2013 Mar; 15(3):241-5. PubMed ID: 23013357
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
7. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes.
Danne T; Lüpke K; Walte K; Von Schuetz W; Gall MA
Diabetes Care; 2003 Nov; 26(11):3087-92. PubMed ID: 14578244
[TBL] [Abstract][Full Text] [Related]
8. Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.
Sørensen LP; Brock B; Mengel A; Rungby J; Moller N; Nielsen S; Vølund A; Schmitz O
Diabet Med; 2010 Jul; 27(7):830-7. PubMed ID: 20636965
[TBL] [Abstract][Full Text] [Related]
9. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups.
Hompesch M; Troupin B; Heise T; Elbroend B; Endahl L; Haahr H; Heinemann L
Diabetes Obes Metab; 2006 Sep; 8(5):568-73. PubMed ID: 16918592
[TBL] [Abstract][Full Text] [Related]
10. Is insulin detemir able to favor a lower variability in the action of injected insulin in diabetic subjects?
Valensi P; Cosson E
Diabetes Metab; 2005 Sep; 31(4 Pt 2):4S34-4S39. PubMed ID: 16389896
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection.
Lucidi P; Porcellati F; Marinelli Andreoli A; Carriero I; Candeloro P; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2015 Dec; 38(12):2204-10. PubMed ID: 26358287
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study.
Lucidi P; Porcellati F; Rossetti P; Candeloro P; Cioli P; Marzotti S; Andreoli AM; Fede R; Bolli GB; Fanelli CG
Diabetes Care; 2011 Jun; 34(6):1312-4. PubMed ID: 21498786
[TBL] [Abstract][Full Text] [Related]
13. Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes.
Smeeton F; Shojaee Moradie F; Jones RH; Westergaard L; Haahr H; Umpleby AM; Russell-Jones DL
Diabetologia; 2009 Nov; 52(11):2317-23. PubMed ID: 19707744
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.
Porcellati F; Rossetti P; Busciantella NR; Marzotti S; Lucidi P; Luzio S; Owens DR; Bolli GB; Fanelli CG
Diabetes Care; 2007 Oct; 30(10):2447-52. PubMed ID: 17623819
[TBL] [Abstract][Full Text] [Related]
15. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
Scholtz HE; Pretorius SG; Wessels DH; Becker RH
Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of adiposity on pharmacodynamics of basal insulins NPH, glargine, and detemir in type 2 diabetes mellitus.
Porcellati F; Lucidi P; Rossetti P; Candeloro P; Andreoli AM; Marzotti S; Cioli P; Bolli GB; Fanelli CG
Diabetes Care; 2011 Dec; 34(12):2521-3. PubMed ID: 21972412
[TBL] [Abstract][Full Text] [Related]
18. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
